Side-by-side · Research reference

DSIPvsGHK-Cu

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited

BHuman-MechanisticReviewed8/47 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

GHK-Cu

Tripeptide · Skin / Hair / Wound Healing

1–2 mgSQ dosePickart 2018

HumanMechanisticPickart 2018 Zink 2003

HoursHalf-life

SQ or topical · Local · Daily or 2-3×/week

01Mechanism of Action

Parameter

DSIP

GHK-Cu

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018 Zink 2003

Feedback intact?

—

Replaces declining endogenous levels

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018

Antibody development

—

02Dosage Protocols

Parameter

DSIP

GHK-Cu

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

—

Frequency

Once daily, pre-sleep

Daily or 2–3× per week (SQ)

Lower / starter dose

50 mcg pre-sleep

0.5 mg / day SQ

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Human-mechanistic + topical clinical studiesPickart 2018

Duration

8–12 weeks per cycle

8–12 weeks for visible skin / hair effect

Reconstitution

Bacteriostatic water

Bacteriostatic water; light-protected

Timing

30–60 min pre-sleep

No specific time; evening preferred for topicals

Half-life

Short plasma; CNS effects last hours

Hours (estimated; rapid tissue uptake)

Standard SQ dose

—

1–2 mg / dayPickart 2018

Anecdotal injectable range; topical creams use 0.1–2% solutions.

Topical concentration

—

0.1–2.0% in serum / cream

04Side Effects & Safety

Parameter

DSIP

GHK-Cu

Injection site reaction

Mild irritation

Erythema, mild pruritus (common)

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

—

Pregnancy / OB

Avoid

Avoid topical and SQ — insufficient data

Topical irritation

—

Mild redness, transient stinging

Copper accumulation

—

Theoretical with very high chronic doses

Allergic reaction

—

Rare hypersensitivity to copper

Wilson disease

—

Contraindicated

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

GHK-Cu

·Wilson disease (copper-overload disorder)
·Pregnancy / breastfeeding
·Known copper hypersensitivity

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

GHK-Cu

·Hemochromatosis (copper-iron crosstalk theoretical)
·Concurrent copper-chelator therapy

05Administration Protocol

Parameter

DSIP

GHK-Cu

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.

2. Injection site

SQ — abdomen. Rotate sites.

SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.

3. Timing

30–60 min pre-sleep.

Anytime; evening preferred. Topical: apply to clean dry skin.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.

5. Needle

29–31G insulin syringe.

30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.

06Stack Synergy

DSIP

— no documented stacks

GHK-Cu

+ BPC-157

Moderate

View BPC-157 →

GHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.

GHK-Cu: 1–2 mg SQ · daily near wound
BPC-157: 250–500 mcg SQ · daily near wound
Primary benefit: Combined ECM rebuilding + angiogenesis for tissue repair